CardioComm Solutions Closes Small Round Equity Financing

Toronto, Ontario--(Newsfile Corp. - September 11, 2016) - Established medical electrocardiogram ("ECG") software and device manufacturer CardioComm Solutions, Inc. (TSXV: EKG) ("CardioComm Solutions" or the "Company") today announced that it has closed a non-brokered private placement equity financing where 2,700,000 units were issued at a price of $0.05 per unit, for gross proceeds of $135,000. Each unit is comprised of one common share of the Company and one common share purchase warrant exercisable for two years for an additional share at a price of $0.075. The securities issued under the financing are subject to a four month hold period.

The Company intends to use the proceeds towards expanding retail, consumer and investor market awareness of CardioComm Solutions' initiatives for the introduction of newer and cost competitive wireless consumer health and wellness monitoring device in the USA and Canada. The Company will provide additional updates as they are available.

Etienne Grima, Chief Executive Officer of the Company, participated in the financing with the acquisition of 400,000 units. The issuance of units to Mr. Grima under the private placement is considered to be a related party transaction subject to TSX Venture Exchange Policy 5.9 and Multilateral Instrument 61-101 - Protection of Minority Security Holders in Special Transactions. The Company intends to rely on exemptions from the formal valuation and minority shareholder approval requirements provided under sections 5.5(a) and 5.7(a) of Multilateral Instrument 61-101 on the basis that the value of securities to be purchased by Mr. Grima under the private placement did not exceed 25% of the fair market value of the Company's market capitalization.

To learn more about the CardioComm Solutions' products, for more information about the Company's and for further updates regarding HeartCheck™ ECG device integrations, please see the Company's websites www.theheartcheck.com and www.cardiocommsolutions.com.

About CardioComm Solutions

CardioComm Solutions' patented and proprietary technology is used in products for recording, viewing, analyzing and storing electrocardiograms for diagnosis and management of cardiac patients. Products are sold worldwide through a combination of an external distribution network and a North American-based sales team. CardioComm Solutions is headquartered in Toronto, Ontario, Canada. CardioComm Solutions has earned the ISO 13485 certification, is HPB approved, HIPAA compliant and holds clearances for the sale of the HeartCheck™ technologies from the European Union (CE Mark), Australia (TGA), the USA (FDA), China (CFDA) and Canada (Health Canada).

FOR FURTHER INFORMATION PLEASE CONTACT:
Etienne Grima, Chief Executive Officer
1-877-977-9425 x 227
investor.relations@cardiocommsolutions.com
www.cardiocommsolutions.com

Forward-looking statements

This release may contain certain forward-looking statements and forward looking information with respect to the financial condition, results of operations and business of CardioComm Solutions and certain of the plans and objectives of CardioComm Solutions with respect to these items. Such statements and information reflect management's current beliefs and are based on information currently available to management. By their nature, forward-looking statements and forward-looking information involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements and forward-looking information.

In evaluating these statements, readers should not place undue reliance on forward-looking statements and forward-looking information. The Company does not assume any obligation to update the forward-looking statements and forward-looking information contained in this release other than as required by applicable laws, including without limitation, Section 5.8(2) of National Instrument 51-102 (Continuous Disclosure Obligations).

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.